EMPACON L 10/5 TABLET

Product Description

EMPACON L 10/5 TABLET
Empagliflozin 10 mg + Linagliptin 5 mg

Product Description:

EMPACON L 10/5 TABLET is a cutting-edge oral antidiabetic combination designed to deliver comprehensive glycemic control for adults with Type 2 Diabetes Mellitus. Each tablet contains Empagliflozin 10 mg, a proven SGLT2 inhibitor, and Linagliptin 5 mg, a potent DPP-4 inhibitorworking synergistically to lower blood glucose levels, enhance insulin function, and reduce cardiovascular risks.

Key Benefits:

• Dual mechanism targets both fasting and postprandial blood sugar

• Promotes urinary glucose excretion and improves beta-cell response

• Supports weight reduction and lowers HbA1c levels

• May reduce risk of heart failure hospitalization in diabetic patients

Usage/Application:
Recommended as an adjunct to diet and exercise in adults with Type 2 diabetes requiring combination therapy. Ideal for long-term glycemic management under physician supervision.

Composition:

• Empagliflozin 10 mg

• Linagliptin 5 mg

• Excipients: q.s.

Target Buyers:
Trusted by pharmaceutical wholesalers, hospital procurement teams, diabetes care retailers, and bulk drug buyers seeking advanced antidiabetic formulations.

Availability:

Available for bulk supply, contract manufacturing, and private labeling. Open for pan-India distribution partnerships and global export inquiries.